Publications by authors named "Rong-Ji Mu"
Newly diagnosed follicular lymphoma (FL) patients usually received first-line rituximab-based immunochemotherapy (R-chemo). Recently, rituximab plus lenalidomide (R2) emerged as an alternative chemo-free immunotherapy. We performed a comparative analysis of positron emission tomography/computed tomography (PET/CT) in FL undergoing R-chemo or R2.
View Article and Find Full Text PDFDiffuse large B-cell lymphoma (DLBCL) is a highly aggressive subtype of lymphoma with clinical and biological heterogeneity. The International Prognostic Index (IPI) shows great prognostic capability in the era of rituximab, but the biological signatures of IPI remain to be discovered. In this study, we analyzed the clinical data in a large cohort of 2592 patients with newly diagnosed DLBCL.
View Article and Find Full Text PDFArticle Synopsis
- GUIDANCE-01 (NCT04025593) was a phase II trial comparing R-CHOP therapy alone with R-CHOP-X, which includes targeted agents, for patients with newly diagnosed DLBCL based on genetic subtyping.
- The results showed that R-CHOP-X significantly improved complete response rates (88% vs. 66%) and overall response rates (92% vs. 73%) compared to R-CHOP.
- Additionally, R-CHOP-X led to better two-year progression-free survival (88% vs. 63%) and overall survival rates (94% vs. 77%), confirming the benefit of a tailored therapy approach.
Background: The current standard of care for non-bulky diffuse large B-cell lymphoma (DLBCL) patients with an International Prognostic Index (IPI) of 0 is four cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) but whether the same efficacy can be achieved with reduced chemotherapy regimen of four cycles for non-bulky DLBCL patients with an IPI of 1 remains unclear. This study compared four cycles versus six cycles of chemotherapy in non-bulky low-risk DLBCL patients with negative interim positron emission tomography with computed tomography (PET-CT, Deauville 1-3), irrespective of age and other IPI risk factors (IPI 0-1).
Methods: This was an open-label, randomized, phase III, non-inferiority trial.